Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Healthcare outcomes in patients with HIV infection at a tertiary hospital during the COVID-19 pandemic.
Quirós-González V, Rubio R, Pulido F, Rial-Crestelo D, Martín-Jurado C, Hernández-Ros MÁ, López-Jiménez EA, Ferrari JM, Caro-Teller JM, Pinar Ó, Pedrera-Jiménez M, García-Barrio N, Serrano P, Bernal JL. Quirós-González V, et al. Among authors: pulido f. Enferm Infecc Microbiol Clin. 2023 Mar;41(3):149-154. doi: 10.1016/j.eimc.2021.07.013. Epub 2021 Aug 23. Enferm Infecc Microbiol Clin. 2023. PMID: 34456409 Free PMC article.
Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).
Pulido F, Arribas JR, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group. Pulido F, et al. J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):343-50. doi: 10.1097/00126334-200404010-00003. J Acquir Immune Defic Syndr. 2004. PMID: 15097150
[Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results].
Caro-Murillo AM, Castilla J, Pérez-Hoyos S, Miró JM, Podzamczer D, Rubio R, Riera M, Viciana P, López Aldeguer J, Iribarren JA, de los Santos-Gil I, Gómez-Sirvent JL, Berenguer J, Gutiérrez F, Saumoy M, Segura F, Soriano V, Peña A, Pulido F, Oteo JA, Leal M, Casabona J, del Amo J, Moreno S; Grupo de trabajo de la Cohorte de la Red de Investigación en Sida (CoRIS). Caro-Murillo AM, et al. Among authors: pulido f. Enferm Infecc Microbiol Clin. 2007 Jan;25(1):23-31. doi: 10.1157/13096749. Enferm Infecc Microbiol Clin. 2007. PMID: 17261243 Spanish.
Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
Pérez-Elias MJ, Sánchez-Conde M, Soriano V, Mallolas J, Luque I, Rodríguez-Alcántara F; Fosamprenavir Expanded Access Program Group. Pérez-Elias MJ, et al. Enferm Infecc Microbiol Clin. 2009 Jan;27(1):28-32. doi: 10.1016/j.eimc.2008.05.002. Epub 2009 Jan 9. Enferm Infecc Microbiol Clin. 2009. PMID: 19218000 Clinical Trial.
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression.
Pulido F, Pérez-Valero I, Delgado R, Arranz A, Pasquau J, Portilla J, Rubio R, González-García J, Miralles P, Pérez-Elías MJ, Ocampo A, Hernando A, Estrada V, Clotet B, Podzamczer D, Arribas JR. Pulido F, et al. Antivir Ther. 2009;14(2):195-201. doi: 10.1177/135965350901400210. Antivir Ther. 2009. PMID: 19430094
[Factors related to non-prescription of tuberculin skin testing in a cohort of HIV-infected people].
Díaz A, Diez M, Bleda MJ, Aldamiz M, Camafort M, Camino X, Cepeda C, Costa A, Ferrero O, Geijo P, Iribarren JA, Moreno S, Moreno ME, Labarga P, Pinilla J, Portu J, Pulido F, Rosa C, Santamaría JM, Telenti M, Trapiella L, Trastoy M, Viciana P. Díaz A, et al. Among authors: pulido f. Enferm Infecc Microbiol Clin. 2010 Apr;28(4):215-21. doi: 10.1016/j.eimc.2009.06.008. Epub 2009 Aug 15. Enferm Infecc Microbiol Clin. 2010. PMID: 19683364 Spanish.
340 results